Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 401–500 of 916
Wajapeyee, N., Parajuli, K. R., Chava, S., Pattanayak, R., Manna, D. L. D., Shrestha, D., Yang, E. S.-H., Cai, G., Johnson, D. B., & Gupta, R. (2020) · Oncogenesis · doi:10.1038/s41389-020-0228-x · Cited by 31
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
Lau, E., Šedý, J. R., Sander, C., Shaw, M. A., Feng, Y., Scortegagna, M., Claps, G., Robinson, S. E., Cheng, P. F., Srivas, R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.22 · Cited by 27
“Despite the advent of effective targeted monotherapies, such as the mutant BRAF kinase inhibitors vemurafenib (PLX4720) and dabrafenib, most melanomas eventually develop therapeutic resistance that drives relapse and progression 28 .”
Yang, H., Kircher, D. A., Kim, K., Grossmann, A. H., VanBrocklin, M. W., Holmen, S. L., & Robinson, J. P. (2017) · Oncogene · doi:10.1038/onc.2016.526 · Cited by 28
HDAC6 interacts with PTPN1 to enhance melanoma cells progression
Liu, J., Luan, W., Zhang, Y., Gu, J., Shi, Y., Yang, Y., Feng, Z., & Qi, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.145 · Cited by 28
Drug dependence in cancer is exploitable by optimally constructed treatment holidays
Maltas, J., Killarney, S. T., Singleton, K. R., Strobl, M. A. R., Washart, R., Wood, K. C., & Wood, K. B. (2023) · Nature Ecology & Evolution · doi:10.1038/s41559-023-02255-x · Cited by 32
“Drug dependence in BRAF V600E melanoma is driven by the ERK2–JunB/ FRA1–p21 signalling axis 6,7,9 .”
Vemurafenib/dabrafenib and trametinib
Rißmann, R., Hessel, M. H. M., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12651 · Cited by 27
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1001 · Cited by 33
“23 ErbB3 in neural crest-derived cells (55); however, SOX10 in mutant BRAF melanoma cells is associated with repression of EGFR and PDGFR (11).”
InfluentialEpigenetic modulation reveals differentiation state specificity of oncogene addiction
Khaliq, M., Manikkam, M., Martínez, E. D., & Fallahi‐Sichani, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21784-2 · Cited by 29
Vasudevan, S., Flashner-Abramson, E., Alkhatib, H., Chowdhury, S. R., Adejumobi, I. A., Vilenski, D., Stefansky, S., Rubinstein, A. M., & Kravchenko‐Balasha, N. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00190-3 · Cited by 30
Systems analysis identifies miR-29b regulation of invasiveness in melanoma
Andrews, M. C., Cursons, J., Hurley, D., Anaka, M., Cebon, J. S., Behren, A., & Crampin, E. J. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0554-y · Cited by 29
“SOX10 suppression contributes to BRAF- and/or MEK-inhibitor resistance in BRAF mutated melanoma, by activating TGFβ signalling to upregulate EGFR and PDGFRB [57], whilst increasing SOX9 transcript abundance has been observed in breast cancer EMT [58].”
BackgroundThe AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26
Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma
Borbényi-Galambos, K., Erdélyi, K., Ditrói, T., Jurányi, E. P., Szántó, N., Szatmári, R. Z., Czikora, Á., Schmidt, E. E., Garai, D., Cserepes, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.021 · Cited by 28
Nongenetic Mechanisms of Drug Resistance in Melanoma
Rebecca, V. W., & Herlyn, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033533 · Cited by 32
“…(b) receptor tyrosine kinase (RTK) upregulation of IGFR-1 (Villanueva et al. 2010), AXL (Song et al. 2017), PDGFRB (Nazarian et al. 2010), EGFR (Sun et al. 2014), HER3 (Roesch et al. 2016), and c-MET (Hirata et al. 2015); (c) BRAF/CRAF isoform switching (Rebecca & Smalley 2011); (d) metabolic…”
BackgroundInfluentialAnalysis of CRISPR‐Cas9 screens identifies genetic dependencies in melanoma
Christodoulou, E., Rashid, M., Pacini, C., Droop, A., Robertson, H., van Groningen, T., Teunisse, A. F. A. S., Iorio, F., Jochemsen, A. G., Adams, D. J., et al. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12919 · Cited by 30
Ye, L.-F., Huang, Z.-Y., Chen, X., Chen, Z., Wu, S., Ren, C., Hu, M.-T., Bao, H., Jin, Y., Wang, F., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100883 · Cited by 27
Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis
Neuendorf, H. M., Simmons, J. L., & Boyle, G. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1183328 · Cited by 29
“As BRAFi treatment has been demonstrated to promote SOX10-low/EGFR-high expressing cell populations, an independent study investigated the same inhibitor combination in the A375 cell line in the context of SOX10 knockout (Sun et al., 2014).”
BackgroundHow to find the right drug for each patient? Advances and challenges in pharmacogenomics
Kalamara, A., Tobalina, L., & Sáez-Rodríguez, J. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.07.001 · Cited by 28
The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Salès, F., Journe, F., Awada, A. H., Ghanem, G., et al. (2019) · Cancers · doi:10.3390/cancers11081093 · Cited by 28
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers
Chatterjee, N., Pazarentzos, E., Mayekar, M. K., Gui, P., Allegakoen, D. V., Hrustanovic, G., Olivas, V. R., Lin, L., Verschueren, E., Johnson, J. R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.063 · Cited by 26
Huestis, M. P., Cruz, D. D., DiPasquale, A. G., Durk, M. R., Eigenbrot, C. W., Gibbons, P., Gobbi, A., Hunsaker, T., La, H., Leung, D. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02085 · Cited by 26
Konstantakou, E. G., Velentzas, A. D., Anagnostopoulos, A. K., Litou, Z. I., Konstandi, O. A., Giannopoulou, A. F., Anastasiadou, E., Voutsinas, G. E., Tsangaris, G. T., & Stravopodis, D. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171512 · Cited by 28
Howard, A., Bojko, J., Flynn, B. P., Bowen, S., Jungwirth, U., & Walko, G. (2022) · Experimental Dermatology · doi:10.1111/exd.14655 · Cited by 29
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death
Rosenbaum, S. R., Caksa, S., Stefanski, C. D., Trachtenberg, I. V., Wilson, H. P., Wilski, N. A., Ott, C. A., Purwin, T. J., Haj, J. I., Pomante, D., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0290 · Cited by 27
Overcoming MCL-1-driven adaptive resistance to targeted therapies
Wood, K. C. (2020) · Nature Communications · doi:10.1038/s41467-020-14392-z · Cited by 28
Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance.
Martínez‐Cardús, A., Vizoso, M., Morán, S., & Manzano, J. L. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.06.20 · Cited by 36
“In addition, cancer cells frequently can adapt to and evade the drug effects, either by developing new favourable molecular mechanisms or by activating alternative compensatory pathways that can bypass the effects of the therapy (acquired or secondary resistance) (28,29).”
BackgroundLoss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition
Ji, Z., Njauw, C.-N. J., Guhan, S. M., Kumar, R., Reddy, B. Y., Rajadurai, A., Flaherty, K. T., & Tsao, H. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.041 · Cited by 24
Pillai, M., Chen, Z., Jolly, M. K., & Li, C. (2022) · iScience · doi:10.1016/j.isci.2022.105499 · Cited by 25
Anastasi, S., Lamberti, D., Alemà, S., & Segatto, O. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.001 · Cited by 24
Small-molecule binding sites to explore protein–protein interactions in the cancer proteome
Xu, D. D., Jalal, S. I., Sledge, G. W., & Meroueh, S. O. (2016) · Molecular BioSystems · doi:10.1039/c6mb00231e · Cited by 24
Spender, L. C., Ferguson, G. J., Liu, S., Cui, C., Girotti, M. R., Sibbet, G. J., Higgs, E. B., Shuttleworth, M. K., Hamilton, T., Lorigan, P. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13226 · Cited by 26
“Increased transforming growth factor-beta (TGFβ) secretion may be part of the therapy-induced secretome, and has been implicated in both in vitro derived drug resistance [20] and in vemurafenib-resistant patient material [21].”
BackgroundInfluentialModelling bistable tumour population dynamics to design effective treatment strategies
Akhmetzhanov, A. R., Kim, J. W., Sullivan, R. J., Beckman, R. A., Tamayo, P., & Yeang, C. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.05.005 · Cited by 31
Program, N. C. S., Fufa, T., Baxter, L. L., Wedel, J. C., Gildea, D. E., Loftus, S. K., & Pavan, W. J. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0297-2 · Cited by 40
“Recent studies have provided evidence that SOX10 occupies a key regulatory node in the response to MAPK signaling in the nucleus: SOX10 emerged from a shRNA screen for genes that confer resistance to BRAF and MEK inhibitors via upregulation of EGFR and PDGFRB [47], and SOX10 is directly phosphorylated by ERK as part o…”
BackgroundDas, I., Wilhelm, M., Höiom, V., Franco‐Márquez, R., Svedman, F. C., Hansson, J., Tuominen, R., & Brage, S. E. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1875-8 · Cited by 25
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
Cybulska-Stopa, B., Rogala, P., Czarnecka, A. M., Galus, Ł., Dziura, R., Rajczykowski, M., Kubiatowski, T., Wiśniewska, M., Gęga-Czarnota, A., Teterycz, P., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000662 · Cited by 24
Engineering Multidimensional Evolutionary Forces to Combat Cancer
McCoach, C. E., & Bivona, T. G. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1196 · Cited by 25
Metastatic melanoma moves on: translational science in the era of personalized medicine
Levesque, M. P., Cheng, P. F., Raaijmakers, M. I. G., Saltari, A., & Dummer, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9658-0 · Cited by 26
Koplev, S., Longden, J., Ferkinghoff‐Borg, J., Bjerregård, M. B., Cox, T. R., Erler, J. T., Pedersen, J. T., Völlmy, F., Sommer, M. O. A., & Linding, R. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.095 · Cited by 26
Anti‐cancer therapy: senescence is the new black
de Oliveira, R. L., & Bernards, R. (2018) · The EMBO Journal · doi:10.15252/embj.201899386 · Cited by 25
“Importantly, even some advanced cancer cells can be induced to enter a state of senescence by excessive oncogenic signalling or by chemotherapy treatment (Ewald et al , 2010; Sun et al , 2014).”
Self-citationSwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics
Singer, F., Irmisch, A., Toussaint, N. C., Grob, L., Singer, J., Thurnherr, T., Beerenwinkel, N., Levesque, M. P., Dummer, R., Quagliata, L., et al. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0680-0 · Cited by 26
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Das, I., Gad, H., Bräutigam, L., Pudelko, L., Tuominen, R., Höiom, V., Almlöf, I., Rajagopal, V., Hansson, J., Helleday, T., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-019-0488-1 · Cited by 23
Grigore, F., Yang, H., Hanson, N. D., VanBrocklin, M. W., Sarver, A. L., & Robinson, J. P. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.006 · Cited by 25
Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
Pathria, G., Garg, B., Borgdorff, V., Garg, K., Wagner, C., Superti‐Furga, G., & Wagner, S. N. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.369 · Cited by 26
Duggan, M. C., Stiff, A. R., Bainazar, M. A., Regan, K., Salavaggione, G. N. O., Maharry, S. E., Blachly, J. S., Krischak, M. K., Walker, C. J., Latchana, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704371114 · Cited by 23
Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention
Dias, M. H., & Bernards, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12979 · Cited by 23
Self-citationKluszczyńska, K., & Czyż, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020965 · Cited by 23
Zhang, S., Yang, Z. H., & Qi, F. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05227-2 · Cited by 24
Krayem, M., Aftimos, P. G., Najem, A., van den Hooven, T., van den Berg, A., Hovestad-Bijl, L., de Wijn, R., Hilhorst, R., Ruijtenbeek, R., Sabbah, M., et al. (2020) · Cancers · doi:10.3390/cancers12020512 · Cited by 22
“Unfortunately, resistance developed in all patients [22].”
BackgroundBiondini, M., Kiepas, A., El–Houjeiri, L., Annis, M. G., Hsu, B. E., Fortier, A.-M., Morin, G., Martina, J. A., Sirois, I., Aguilar‐Mahecha, A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02206-z · Cited by 22
Self-citationFarnsworth, D., Inoue, Y., Johnson, F. D., de Rappard-Yuswack, G., Lu, D., Shi, R., Ma, L. I. J., Mattar, M. S., Somwar, R., Ladanyi, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00328-x · Cited by 24
Wang, X., Yang, L., Yu, C., Ling, X., Guo, C., Chen, R., Li, D., & Liu, Z. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107230 · Cited by 21
A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues
Welinder, C., Pawłowski, K., Sugihara, Y., Yakovleva, M., Jönsson, G. B., Ingvar, C., Lundgren, L., Baldetorp, B., Olsson, H. L., Rezeli, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123661 · Cited by 24
“However, even with these newer treatments drug resistance may also develop [11].”
Galliker, N., Murer, C., Kamarashev, J. A., Dummer, R., & Goldinger, S. M. (2015) · European Journal of Dermatology · doi:10.1684/ejd.2014.2512 · Cited by 21
“Moreover, combination of selective BRAF and MEK inhibitors is a strategy to delay the development of resistance [11-14].”
BackgroundActivity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition
Sharma, R., Smalley, I., Spence, P., Sondak, V. K., Smalley, K. S. M., & Koomen, J. M. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00613 · Cited by 21
“Signal initiation from EphA2 and EGFR is crucial for downstream signaling to promote survival of BRAFi resistant cell lines.(34, 59, 60) EphA2 is a receptor tyrosine kinase known to bind to FAK1 leading to recruitment of Shp2, which dephosphorylates FAK1 and inhibits integrin signaling in a ligand dependent manner.”
BackgroundAcquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
Krayem, M., Najem, A., Journé, F., Morandini, R., Salès, F., Awada, A. H., & Ghanem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25879 · Cited by 24
“Thus, our data propose a strong molecular rationale for the use of “drug holiday” in BRAF inhibitor regimes to bring about longer lasting clinical responses in V600EBRAF melanoma as suggested by Sun and colleagues [28].”
BackgroundRetractedSalt doping to improve thermoelectric power factor of organic nanocomposite thin films
Stevens, D. L., Gamage, G. A., Ren, Z., & Grunlan, J. C. (2020) · RSC Advances · doi:10.1039/d0ra00763c · Cited by 21
Frazao, A., Rethacker, L., Jeudy, G., Colombo, M., Pasmant, É., Avril, M., Toubert, A., Moins‐Teisserenc, H., Roelens, M., Dalac, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000275 · Cited by 23
“29 Moreover, EGFR mutation was associated with higher PD-L1 expression.”
Bioinformatics analysis of lncRNA‑associated ceRNA network in melanoma
Ding, Y., Li, M., Tuersong, T., Zhang, M., Chen, L., & Feng, S. (2021) · Journal of Cancer · doi:10.7150/jca.51851 · Cited by 21
“The development of melanoma is caused by the progression of a benign nevus, sometimes accompanied by sun exposure, physical stimulation, genetic variation, and other factors [3].”
BackgroundAhn, A., Rodger, E. J., Motwani, J., Gimenez, G., Stockwell, P. A., Parry, M. F., Hersey, P., Chatterjee, A., & Eccles, M. R. (2021) · Cancers · doi:10.3390/cancers13174250 · Cited by 22
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
Prasad, C. P., Mohapatra, P., & Andersson, T. (2015) · Cancers · doi:10.3390/cancers7030868 · Cited by 22
Jonas, O. H., Oudin, M. J., Kosciuk, T., Whitman, M. A., Gertler, F. B., Cima, M. J., Flaherty, K. T., & Langer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2722 · Cited by 21
“In BRAF-mutated melanomas, significant adaptive responses (and thus potential targets for therapeutic combinations) have been reported, for instance, involving MEK inhibitors (3, 5).”
BackgroundJastrzebski, K., Thijssen, B., Kluin, R. J. C., de Lint, K., Majewski, I. J., Beijersbergen, R. L., & Wessels, L. F. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2698 · Cited by 21
Self-citationRal Signals through a MAP4 Kinase-p38 MAP Kinase Cascade in C. elegans Cell Fate Patterning
Shin, H., Kaplan, R. E. W., Duong, T., Fakieh, R. A., & Reiner, D. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.011 · Cited by 22
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
SWI/SNF Chromatin Remodeling Enzymes in Melanoma
Dreier, M. R., & de la Serna, I. L. (2022) · Epigenomes · doi:10.3390/epigenomes6010010 · Cited by 22
“SOX10 also plays a role in melanomagenesis and modulates resistance to therapeutics [58,59].”
BackgroundSOX10 , MITF , and microRNAs : Decoding their interplay in regulating melanoma plasticity
Lai, X., Luan, C., Zhang, Z., Wessely, A., Heppt, M. V., Berking, C., & Vera, J. (2025) · International Journal of Cancer · doi:10.1002/ijc.35499 · Cited by 17
“139 The therapeutic implications of SOX10 loss extend beyond conventional targeted therapies, as SOX10-deficient melanoma cells exhibit resistance to oncolytic virus immunotherapy — an approach designed to reverse cancer-associated immune suppression and stimulate antitumor immune responses.”
Response of metastatic glioma to vemurafenib
Leaver, K. E., Zhang, N., Ziskin, J. L., Vogel, H. S., Recht, L. D., & Thomas, R. P. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv054 · Cited by 20
“No large or randomized studies exist to assess the rate of treatment response to vemurafenib among patients with brain tumors, but the response rate of patients with malignant melanoma is approximately 50%.(22,23) In the aforementioned pilot study of BRAF-mutated melanoma with symptomatic brain metastases, there was a…”
BackgroundCrosstalk signaling in targeted melanoma therapy
Meierjohann, S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9659-z · Cited by 21
“In melanoma, only up to one third of tumors express EGFR and are subject to the ERK1/2-EGFR crosstalk [21, 26].”
BackgroundPatil, S. A., Addo, J. K., Deokar, H. S., Sun, S., Wang, J., Li, W., Suttle, D. P., Wang, W., Zhang, R., & Buolamwini, J. K. (2017) · Drug Designing Open Access · doi:10.4172/2169-0138.1000143 · Cited by 20
“Further, we also evaluated the antiproliferative effects of selected compounds against human melanoma skin cancer cell lines A375 and WM164, which are among the most widely used melanoma cell lines with aggressive metastatic behavior [36-38].”
Nejad, M. I., Shi, R., Zhang, X., Gu, L., & Gates, K. S. (2017) · ChemBioChem · doi:10.1002/cbic.201700204 · Cited by 20
Silva, J. M., Deuker, M. M., Baguley, B. C., & McMahon, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12586 · Cited by 28
“ERK1/2 signaling, but eventually leads to a substantial rebound in P-ERK1/2, as previously observed in other contexts as in BRAFT1799A-mutated colorectal or thyroid cancer cell lines (Montero-Conde et al., 2013; Sun et al., 2014).”
ResultPotential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
Olbryt, M. (2022) · Cancers · doi:10.3390/cancers14092315 · Cited by 21
EGF / EGFR ‐ YAP 1/ TEAD 2 signaling upregulates STIM 1 in vemurafenib resistant melanoma cells
Bai, W., Yan, C., Yang, Y., Sang, L., Hao, Q., Yao, X., Zhang, Y., Yu, J. H., Wang, Y., Li, X., et al. (2024) · FEBS Journal · doi:10.1111/febs.17272 · Cited by 19
“Our results also showed that the protein and mRNA levels of EGFR were significantly increased in vemurafenib resistant WM793 cells, in accordance with previous reports [6].”
InfluentialTumor-specific mutations in low-frequency genes affect their functional properties
Erdem‐Eraslan, L., Heijsman, D., de Wit, M., Kremer, A., Sacchetti, A., van der Spek, P. J., Smitt, P. A. E. S., & French, P. J. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1741-1 · Cited by 21
“have shown that expression of EGFR in mutant melanoma cells confers a growth disadvantage that is further strengthened by the addition of EGFR ligand [38].”
Tagami-Nagata, N., Serada, S., Fujimoto, M., Tanemura, A., Nakatsuka, R., Ohkawara, T., Murota, H., Kishimoto, T., Katayama, I., & Naka, T. (2015) · Experimental Dermatology · doi:10.1111/exd.12802 · Cited by 15
Development versus Evolution in Cancer Biology
Marongiu, F., Serra, M., & Laconi, E. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.007 · Cited by 19
Kalimutho, M., Sinha, D., Mittal, D., Srihari, S., Nanayakkara, D. M., Shafique, S., Raninga, P. V., Nag, P., Parsons, K., & Khanna, K. K. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1075-5 · Cited by 20
BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway
Hu, R., Li, Y., Guo, Y., Li, X., Du, S., Liao, M., Hou, H., Sun, H., Zhao, S., Su, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106609 · Cited by 21
Future paradigms for precision oncology
Klement, G. L., Arkun, K., Valík, D., Roffidal, T., Hashemi, A., Klement, C., Carmassi, P., Rietman, E. A., Slabý, O., Mazánek, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9488 · Cited by 21
“Treatment with either vemurafenib (BRAF inhibitor) or trametinib (MEK inhibitor) alone can lead to excellent, but invariably shortlasting responses [54, 55] due to feedback activation of other pathways.[56-58] Because most oncogenic changes tend to hijack physiologic host responses such as inflammation, nullify other…”
BackgroundFritsche‐Guenther, R., Witzel, F., Kempa, S., Brummer, T., Sers, C., & Blüthgen, N. (2016) · Oncotarget · doi:10.18632/oncotarget.6959 · Cited by 21
“Nevertheless, the effects of known and unknown feedbacks and cross-talk are complicating the effort to design effective compounds for patient specific therapy [6, 27, 32, 33].”
BackgroundZhang, Z.-Y., Ding, Y., Ezhilarasan, R., Lhakhang, T. W., Wang, Q., Yang, J., Modrek, A. S., Zhang, H., Tsirigos, A., Futreal, P. A., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00462-7 · Cited by 19
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 21
“While most melanoma patients experience tumor regression and prolonged survival 152 , these medications seldom eradicate the tumor, and a notable percentage of patients still encounter both inherent and acquired resistance 153 .”
BackgroundWu, B. C., Bennett, H. M., Ye, X., Sridhar, A., Eidenschenk, C., Everett, C., Nazarova, E. V., Chen, H.-H., Kim, I. K., DeAngelis, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53227-z · Cited by 22
Roller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 19
Arafeh, R., Flores, K., Keren‐Paz, A., Maik-Rachline, G., Gutkind, N. E., Rosenberg, S. A., Seger, R., & Samuels, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16558-0 · Cited by 19
A Novel Autophagy‐Related lncRNA Gene Signature to Improve the Prognosis of Patients with Melanoma
Ding, Y., Li, T., Li, M., Tuersong, T., Zhang, M., Chen, L., & Feng, S. (2021) · BioMed Research International · doi:10.1155/2021/8848227 · Cited by 20
“Its occurrence is mainly caused by long-term exposure to ultraviolet radiation, sunburn, physical stimulation, and other factors[3].”
Abildgaard, C., Rizza, S., Christiansen, H., Schmidt, S., Dahl, C., Abdul-Al, A., Christensen, A., Filomeni, G., & Guldberg, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-83796-8 · Cited by 20
Gao, A., Tian, Y., Shi, Z., & Yu, L. D. (2015) · BioChip Journal · doi:10.1007/s13206-016-0108-9 · Cited by 18
Management of intracranial melanomas in the era of precision medicine
Young, G. J., Bi, W. L., Wu, W. W., Johanns, T. M., Dunn, G. P., & Dunn, I. F. (2017) · Oncotarget · doi:10.18632/oncotarget.19223 · Cited by 19
“Reversal of acquired EGFR expression has also been observed in resistant cell lines after interruption of therapy [112].”
BackgroundAfasizheva, A., Devine, A., Sheppard, H., Fung, K. L., Vieira, W. D., Blehm, B. H., Kotobuki, Y., Busby, B., Chen, E. I., & Tanner, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2211-7 · Cited by 20
“Moreover, when a separate dataset was examined for RNAseq-based expression levels in human patients, pre- and post-vemurafenib (first column), dabrafenib (second column) and trametinib (third column) treatment, the same pattern of expression (presented as log2 (control)) was observed, with FN1 and TNC, but not other E…”
ResultSalama, Y., Jaradat, N. A., Hattori, K., & Heissig, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158151 · Cited by 19
“Other studies showed that six out of 16 melanoma tumors acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors [54], and acquired resistance was found with the overexpression of signaling receptors like EGFR, PDGFRβ, or MET that reactivation the MAPK pathway.”
BackgroundSelected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Harwood, S. J., Smith, C. R., Lawson, J. D., & Ketcham, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087373 · Cited by 17
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
van Not, O. J., van den Eertwegh, A. J. M., Haanen, J. B. A. G., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., de Groot, J. W. B., Hospers, G. A. P., et al. (2024) · Cancer · doi:10.1002/cncr.35178 · Cited by 17
“Sun et al. 35 raised the hypothesis based on preclinical and translational data that some patients who develop resistance to BRAFi(/MEKi) therapy may benefit from a period free of targeted therapy.”
BackgroundSelf-citationCEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness
Abou‐Hamad, J., Hodgins, J. J., de Souza, C. T., Garland, B., Labrèche, C., Marotel, M., Gibson, C., Delisle, S., Pascoal, J., Auer, R. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105524 · Cited by 17
“Supporting this, suppression of Sox10 induces EGFR, PDGFRb and confers resistance to BRAF inhibitors.(22) SOX10 typically act in concert with its downstream target MITF, a bHLH transcription factor.”
BackgroundZhang, R., Du, W., Zhang, Y., Zheng, J., & Pei, D. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1999-x · Cited by 17
Consequences of feedback in signal transduction for targeted therapies
Klinger, B., & Blüthgen, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140130 · Cited by 20
Radiotherapy with BRAF Inhibitor Therapy for Melanoma: Progress and Possibilities
Zahnreich, S., Mayer, A., Loquai, C., Grabbe, S., & Schmidberger, H. (2015) · Future Oncology · doi:10.2217/fon.15.297 · Cited by 18
MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma
Vu, H. L., Rosenbaum, S. R., Capparelli, C., Purwin, T. J., Davies, M. A., Berger, A. C., & Aplin, A. E. (2015) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.11.012 · Cited by 17
“Others have shown upregulation of the RTKs PDGFR β and EGFR upon MEK-ERK1/2 inhibition in mutant BRAF melanoma (Shi et al, 2014, Sun et al, 2014).”
Pathria, G., Garg, B., Garg, K., Wagner, C., & Wagner, S. N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14713 · Cited by 18
Larribère, L., Kuphal, S., Sachpekidis, C., Sachindra, Hüser, L., Bosserhoff, A., & Utikal, J. S. (2018) · Cancers · doi:10.3390/cancers10110451 · Cited by 28
Scrotal angiokeratoma (Fordyce): histopathological and ultrastructural findings.
Gioglio, L., Porta, C., Moroni, M., Nastasi, G., & Gangarossa, I. (1992) · PubMed · Cited by 18
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.